ImmunoGen, Inc.
IMGNDrugs in Pipeline
11
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Paclitaxel
Epithelial Ovarian Cancer
BB-10901
Small Cell Lung Cancer
Vacc-4x
HIV-1 Infection
Sterile water
HIV I Infection
Carboplatin
Epithelial Ovarian Cancer
SARS-CoV-2 DNA Vaccine (ICCOV)
COVID-19
Romidepsin
HIV I Infection
Lenalidomide
HIV-1 Infection
Vacc-C5/GM-CSF
HIV-1 Infection
IMGC936
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Paclitaxel | Phase 3 | Epithelial Ovarian Cancer | - | - |
BB-10901 | Phase 2 | Small Cell Lung Cancer | - | - |
Vacc-4x | Phase 2 | HIV-1 Infection | - | - |
Sterile water | Phase 2 | HIV I Infection | - | - |
Carboplatin | Phase 2 | Epithelial Ovarian Cancer | - | - |
SARS-CoV-2 DNA Vaccine (ICCOV) | Phase 2 | COVID-19 | - | - |
Romidepsin | Phase 2 | HIV I Infection | - | - |
Lenalidomide | Phase 2 | HIV-1 Infection | - | Patent 2028 |
Vacc-C5/GM-CSF | Phase 2 | HIV-1 Infection | - | - |
IMGC936 | Phase 2 | Advanced Solid Tumor | - | - |
Epithelial Ovarian Cancer
3 drugs in this indication
HIV-1 Infection
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in ImmunoGen, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in ImmunoGen, Inc.'s (IMGN) pipeline across Phase 3, Phase 2. Its lead program is Mirvetuximab Soravtansine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ImmunoGen, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ImmunoGen, Inc. (IMGN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMGN biotech catalysts?→
Add IMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ImmunoGen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.